ABION Inc. (KOSDAQ:203400)
South Korea · Delayed Price · Currency is KRW 2,290.00
-150.00 (-6.15%)
At close: Apr 2, 2026
ABION Revenue
In the year 2025, ABION had annual revenue of 880.14M KRW with 15.86% growth. ABION had revenue of 66.43M in the quarter ending December 31, 2025, a decrease of -69.48%.
Revenue
880.14M
Revenue Growth
+15.86%
P/S Ratio
234.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
206.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 880.14M | 120.45M | 15.86% |
| Dec 31, 2024 | 759.68M | -514.62M | -40.38% |
| Dec 31, 2023 | 1.27B | -1.23B | -49.16% |
| Dec 31, 2022 | 2.51B | 868.02M | 52.98% |
| Dec 31, 2021 | 1.64B | -355.32M | -17.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 56.67B |
| NIBEC | 32.96B |
| Genome & Company | 24.59B |
| Prestige Biologics | 19.24B |
| S.Biomedics | 16.96B |
| QuadMedicine | 13.11B |
| Kangstem Biotech | 12.77B |
| TiumBio | 12.29B |